Skip to content
Agree.net – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
June 13, 2026
FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
June 9, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
June 2, 2026
Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
May 31, 2026
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
Lilly announces three acquisitions to build infectious disease portfolio
May 26, 2026
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
May 25, 2026
Lilly to participate in Bernstein’s 42nd Annual Strategic Decisions Conference
May 18, 2026
Lilly and UNICEF collaborate to give millions of children a healthier start
May 14, 2026
1
2
3
Next Page
→